Point72 Middle East FZE’s BridgeBio Pharma BBIO Stock Holding History

Point72 Middle East FZE’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-63,978	Closed	-$1.69M	–	1509
2023 Q3	$1.69M	Buy	+63,978	New	+$1.82M	0.06%	399
2023 Q1	–	Sell	-19,791	Closed	-$151K	–	1655
2022 Q4	$151K	Buy	+19,791	New	+$189K	0.01%	1145

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Point72 Middle East FZE's BBIO Position: Q4 2023 in Review

Point72 Middle East FZE sold out of BridgeBio Pharma (BBIO) in Q4 2023, closing a stake of 63,978 shares — an estimated $1.69M sold.

Point72 Middle East FZE first reported a position in BBIO in Q4 2022 and held it in 2 quarters. The position peaked at $1.69M in Q3 2023. 247 funds tracked by Wall St. Rank hold BBIO as of Q4 2023.

Point72 Middle East FZE reported no remaining BridgeBio Pharma position as of Q4 2023 after selling out during the quarter.
Point72 Middle East FZE sold 63,978 BridgeBio Pharma shares in Q4 2023, an estimated $1.69M.
Point72 Middle East FZE first reported a position in BridgeBio Pharma in Q4 2022 and held it in 2 quarters.
Point72 Middle East FZE's BridgeBio Pharma position peaked at $1.69M in Q3 2023.
247 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2023.

Based on Point72 Middle East FZE's 13F filing for Q4 2023, filed 14 Feb 2024.